Literature DB >> 25144909

The effects of prior authorization policies on medicaid-enrolled children's use of antipsychotic medications: evidence from two mid-Atlantic states.

Bradley D Stein1, Emily Leckman-Westin, Edward Okeke, Deborah M Scharf, Mark Sorbero, Qingxian Chen, Ka Ho Brian Chor, Molly Finnerty, Jennifer P Wisdom.   

Abstract

OBJECTIVE: The purpose of this study was to examine the impact of prior authorization policies on the receipt of antipsychotic medication for Medicaid-enrolled children.
METHODS: Using de-identified administrative Medicaid data from two large, neighboring, mid-Atlantic states from November 2007 through June 2011, we identified subjects <18 years of age using antipsychotics, from the broader group of children and adolescents receiving behavioral health services or any psychotropic medication. Prior authorization for antipsychotics was required for children in State A <6 years of age from September 2008, and for children <13 years of age from August 2009. No such prior authorizations existed in State B during that period. Filled prescriptions were identified in the data using national drug codes. Using a triple-difference strategy (using differences among the states, time periods, and differences in antidepressant prescribing rates among states over the same time periods), we examined the effect of the prior authorization policy on the rate at which antipsychotic prescriptions were filled for Medicaid-enrolled children and adolescents.
RESULTS: The impact of prior authorization policies on antipsychotic medication use varied by age: Among 6-12 year old children, the impact of the prior authorization policy on antipsychotic medication prescribing was a modest but statistically significant decrease of 0.47% after adjusting for other factors; there was no effect of the prior authorization among children 0-5 years.
CONCLUSIONS: Prior authorization policies had a modest but statistically significant effect on antipsychotic use in 6-12 year old children, but had no impact in younger children. Future research is needed to understand the utilization and clinical effects of prior authorization and other policies and interventions designed to influence antipsychotic use in children.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25144909      PMCID: PMC4162428          DOI: 10.1089/cap.2014.0008

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  52 in total

1.  Annotation: The use of psychotropic medications in children: an American view.

Authors:  Mark L Wolraich
Journal:  J Child Psychol Psychiatry       Date:  2003-02       Impact factor: 8.982

2.  Who are the new users of antipsychotic medications?

Authors:  Marisa Elena Domino; Marvin S Swartz
Journal:  Psychiatr Serv       Date:  2008-05       Impact factor: 3.084

3.  Assessment of changes in utilization of health-care services after implementation of a prior authorization policy for atypical antipsychotic agents.

Authors:  Amy Walthour; Lynne Seymour; Randall Tackett; Matthew Perri
Journal:  Ann Pharmacother       Date:  2010-04-13       Impact factor: 3.154

4.  National trends in the use of psychotropic medications by children.

Authors:  Mark Olfson; Steven C Marcus; Myrna M Weissman; Peter S Jensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-05       Impact factor: 8.829

5.  "Real world" atypical antipsychotic prescribing practices in public child and adolescent inpatient settings.

Authors:  Elizabeth Pappadopulos; Peter S Jensen; Sarah B Schur; James C MacIntyre; Scott Ketner; Kimberly Van Orden; Jeffrey Sverd; Sadhana Sardana; David Woodlock; Robert Schweitzer; David Rube
Journal:  Schizophr Bull       Date:  2002       Impact factor: 9.306

6.  Trends in the prescribing of psychotropic medications to preschoolers.

Authors:  J M Zito; D J Safer; S dosReis; J F Gardner; M Boles; F Lynch
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

7.  The continuing shortage of child and adolescent psychiatrists.

Authors:  Christopher R Thomas; Charles E Holzer
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-09       Impact factor: 8.829

8.  Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.

Authors:  Stephen B Soumerai; Fang Zhang; Dennis Ross-Degnan; Daniel E Ball; Robert F LeCates; Michael R Law; Tom E Hughes; Daniel Chapman; Alyce S Adams
Journal:  Health Aff (Millwood)       Date:  2008-04-01       Impact factor: 6.301

9.  Child and adolescent psychiatry workforce: a critical shortage and national challenge.

Authors:  Wun Jung Kim
Journal:  Acad Psychiatry       Date:  2003

10.  The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.

Authors:  Meredith Matone; Russell Localio; Yuan-Shung Huang; Susan dosReis; Chris Feudtner; David Rubin
Journal:  Health Serv Res       Date:  2012-09-04       Impact factor: 3.402

View more
  9 in total

1.  Advancing the Quality of Pediatric Antipsychotic Use: Maybe It Takes a PAL.

Authors:  Julie Magno Zito
Journal:  Health Serv Res       Date:  2017-04       Impact factor: 3.402

2.  Patterns of Antipsychotic Prescribing by Physicians to Young Children.

Authors:  Haiden A Huskamp; Marcela Horvitz-Lennon; Ernst R Berndt; Sharon-Lise T Normand; Julie M Donohue
Journal:  Psychiatr Serv       Date:  2016-07-15       Impact factor: 3.084

Review 3.  Dosing and Monitoring: Children and Adolescents.

Authors:  Glenn S Hirsch
Journal:  Psychopharmacol Bull       Date:  2018-02-05

4.  Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.

Authors:  Ayse Akincigil; Thomas I Mackie; Sharon Cook; Robert J Hilt; Stephen Crystal
Journal:  Health Serv Res       Date:  2020-06-21       Impact factor: 3.402

5.  Decrease in Statewide Antipsychotic Prescribing after Implementation of Child and Adolescent Psychiatry Consultation Services.

Authors:  Rebecca P Barclay; Robert B Penfold; Donna Sullivan; Lauren Boydston; Julia Wignall; Robert J Hilt
Journal:  Health Serv Res       Date:  2017-04       Impact factor: 3.402

6.  Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015.

Authors:  Rachel L Hulkower; Meghan Kelley; Lindsay K Cloud; Susanna N Visser
Journal:  Public Health Rep       Date:  2017-10-26       Impact factor: 2.792

7.  Use of Pooled State Administrative Data for Mental Health Services Research.

Authors:  Kimberly Eaton Hoagwood; Susan Essock; Joseph Morrissey; Anne Libby; Sheila Donahue; Benjamin Druss; Molly Finnerty; Linda Frisman; Meera Narasimhan; Bradley D Stein; Jennifer Wisdom; Judy Zerzan
Journal:  Adm Policy Ment Health       Date:  2016-01

8.  Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018.

Authors:  Molly Candon; Siyuan Shen; Oluwatoyin Fadeyibi; Joseph L Smith; Aileen Rothbard
Journal:  BMC Psychiatry       Date:  2021-10-22       Impact factor: 3.630

9.  Trends Over Time in Antipsychotic Initiation at a Large Children's Health Care System.

Authors:  Laura J Chavez; Kelly J Kelleher; Arne Beck; Gregory N Clarke; Robert B Penfold
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-06       Impact factor: 3.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.